Search clinical trials for: Valsartan 160mg

Total 1908 results

Damanhour University

Recruiting

Fenofibrate Role in Breast Cancer Patients

Breast Cancer

Egypt
GlaxoSmithKline

Withdrawn

GSK2190915 Pediatric Study

Asthma
University of Patras

Completed

High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Platelet Reactivity

Greece
AstraZeneca

Completed

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Renal Impairment

United States
Phloronol Inc.
Worldwide Clinical Trials

Completed

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Safety Issues

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Samsung Medical Center
Dong-A Pharmaceutical Co., Ltd.

Unknown

Zydena on Cognitive Function of Alzheimer's Disease Patients

Alzheimer's Disease

Korea, Republic of
Inmagene LLC

Recruiting

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
Shandong New Time Pharmaceutical Co., LTD

Completed

Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg

Bioequivalence

China
Henry M. Jackson Foundation for the Advancement...
Gilead Sciences

Withdrawn

Antiretroviral Therapy for Acute HIV Infection

HIV Infections

Uganda
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
Yuhan Corporation

Completed

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension | Hyperlipidemia

Korea, Republic of
Vanderbilt University

Completed

Effect of DPP4 Inhibition on Vasoconstriction

Type 2 Diabetes Mellitus

United States
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Cardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic Peptides

United States
HK inno.N Corporation

Completed

Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects

Healthy

Korea, Republic of
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PRECISION-BP)

Cardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone System

United States
Swiss Federal Institute of Technology
Mahidol University

Unknown

Defining a Dosing Regimen With Maximal Absorption for Oral Iron Supplementation During Pregnancy

Iron Deficiency Anemia of Pregnancy

Thailand
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Novartis

Completed

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Hypertension
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Chronic Heart Failure
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

Hypercholesterolemia

Japan
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Allist Pharmaceuticals, Inc.

Recruiting

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR)

NSCLC

China
Allist Pharmaceuticals, Inc.

Withdrawn

Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

NSCLC

China
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary
Novartis Pharmaceuticals

Completed

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Heart Failure

United States
LanZhou University

Unknown

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Hypertension
Hannover Medical School
DLR German Aerospace Center

Withdrawn

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure (ARNI-Sy)

Heart Failure

Germany
MedImmune LLC

Completed

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Healthy Volunteers

United Kingdom
The Children's Hospital of Zhejiang University...

Unknown

Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules

Henoch Schönlein Purpura Nephritis

China
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Essential Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

Heart Failure

United States
Nottingham University Hospitals NHS Trust
University of Nottingham; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis... and other collaborators

Completed

Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 (GIFT-CF2)

Cystic Fibrosis

United Kingdom
Bio-innova Co., Ltd

Not yet recruiting

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Healthy Subjects
University of Zurich
Novartis Pharmaceuticals

Completed

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction (VASCEND)

Heart Failure

Switzerland
Guangdong Provincial People's Hospital

Unknown

Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure (ESARHD-HF)

Heart Failure | Hemodialysis Complication

China
Dong-A University

Completed

The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling (VALID)

Myocardial Infarction

Korea, Republic of
Novartis

Completed

A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure

Chronic Heart Failure

United States
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

Non-Alcoholic Steatohepatitis (NASH)

China
Novartis Pharmaceuticals

Completed

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

Heart Failure With Preserved Ejection Fraction

Colombia, Romania, United States, Austria, Belgium, Estonia, Turkey, Germany, Netherlands, Italy, Spain, Thailand, Argentina, France, Bulgaria, Hungary, Israel, Peru, Lithuania, Guatemala, India, Russian Federation, Denmark, Mexico, Slo... and more
Innocoll
Premier Research Group plc

Completed

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

Hernioplasty

United States
University of Leipzig

Active, not recruiting

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure (ARNI-PVA)

Heart Failure With Reduced Ejection Fraction

Germany
Novartis Pharmaceuticals

Completed

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure (PROVIDE-HF)

Heart Failure, Systolic

United States
University Hospital, Toulouse

Terminated

Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure (B2AN-SNS)

Heart Failure

France

Search clinical trials for: Valsartan 160mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations